Immune checkpoint inhibitors (ICIs) are a type of cancer treatment that work by over-activating the immune system to find and kill cancer cells. This type of treatment can sometimes lead to side effects that look like autoimmune diseases (diseases where the immune system attacks the body). We want to collects samples and clinical data from cancer patients taking ICI therapy to understand why some patients get side effects and others don't.
We will ask you to provide samples of blood, urine, stool, and a swab of your cheek before your first dose of immunotherapy and at several oncology visits. We will ask for permission to review your medical chart. We will ask to use medical waste tissue or fluids if you have any clinical procedures while you are in the study. We will also ask permission to collect additional biopsies for research if you have any biopsy procedures during the study.
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA
Rumey Ishizawar
LCCC - Clinical Trials
Clinical or Medical
Observational
Cancer (Bladder, Brain and Other Nervous System, Breast, Colorectal, Cervical, Head and Neck, Kidney, Liver, Lung, Melanoma, Pancreatic, Prostate, Sarcoma (bone and soft tissue), Stomach and Esophageal, Thyroid and Other Gland/Endocrine, Other Cancers, Leukemia, Phase 1 Trials (all cancers), Lymphoma, Multiple Myeloma, Uterine (endometrial), Ovarian)
Immune System/Infections
18-0560
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
